Psilocybin for Chronic Pelvic Pain (CPP) in... — Clinical Trial Details | Blossom

Psilocybin for Chronic Pelvic Pain (CPP) in... — Clinical Trial Details | Blossom

Participants

Ages

18 – 45

Sexes

female

BMI

-

Psychosis History

-

Inclusion Criteria

Inclusion Criteria:
Assigned female at birth, age 18-45 years (pre-menopause)
CPP for at least 6 months or longer with central sensitization, diagnosed by a provider who specializes in CPP (e.g. MD, DO, NP)
CPP with central sensitization includes endometriosis, adenomyosis, uterine fibroids, pelvic congestion, other pelvic inflammatory diseases, irritable bowel syndrome, inflammatory bladder disorders, myalgias, or any combination of the aforementioned
Failing at least 1 treatment for CPP. Failed conventional interventions include pharmacotherapy, non-pharmacotherapy (bladder installations, neuromodulation, trigger point injections, anesthetic blocks, surgery), physical therapy, and/or psychotherapy (e.g. Cognitive Behavioral Therapy)
Participants will be generally healthy with no exclusionary physical or mental health conditions.

Exclusion Criteria

Exclusion Criteria:
Pelvic pain that is not defined as chronic (e.g. acute pelvic or vaginal infections such as sexually transmitted infections, urinary tract infections, pregnancy)
Have a history of or a current primary psychotic disorder or bipolar disorder type 1
Current use of lithium.
Ketamine-assisted therapy within 12 weeks of the baseline visit (V3) or hallucinogen use within 6 months of study enrollment (e.g. psilocybin at a dose of 10 mg or 1 gram mushroom or greater, LSD, MDMA, DMT)
Cannabis use (THC, CBD). If willing to taper before the baseline visit (V3) the participant can be included.
A positive urine drug test for illicit substance use
a score of 5 or greater on the Alcohol Use Disorder Identification Test- Consumption (AUDIT-C) indicating heavy alcohol use
Suicidal ideation or serious suicide risk as determined by C-SSRS, if baseline score is 4 or greater.
Uncontrolled hypertension, cardiovascular disease, chronic neurologic disorders (e.g. Parkinson's disease, dementia, multiple sclerosis, epilepsy)
Have any current problem which, in the opinion of the investigator or study physician, might interfere with participation